NCT03226574View on ClinicalTrials.gov

Study to Evaluate Safety and MTD of Epidural Resiniferatoxin Injection for Treatment of Intractable Cancer Pain

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

September 1, 2017

Primary Completion Date

March 18, 2020

Study Completion Date

June 18, 2020

Conditions
Intractable Cancer Pain
Interventions
DRUG

Resiniferatoxin

single dose (0.4, 1, 2, 4, 8,15, 25 or 35 mcg), epidural injection

Trial Locations (4)

27710

Duke University Medical Center, Durham

33136

University of Miami/Sylvester Comprehensive Cancer Center, Miami

77004

Hermann Drive Surgical Hospital, Houston

02115

Brigham & Women's Hospital, Boston

All Listed Sponsors
lead

Sorrento Therapeutics, Inc.

INDUSTRY

NCT03226574 - Study to Evaluate Safety and MTD of Epidural Resiniferatoxin Injection for Treatment of Intractable Cancer Pain | Biotech Hunter | Biotech Hunter